Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 195

Sort by

Sort Order Select

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database

Jonathan C. Roberts, Lynn M Malec, MD, Imrran Halari, Sarah Hale, Abiola Oladapo, Robert Sidonio

Blood (2019) 134 (Supplement_1): 2117.

https://doi.org/10.1182/blood-2019-122164

Published: 2019

Journal Articles

Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study

Lorenzo Gervaso, MD, Shyam K Poudel, MD, Joanna Roopkumar, MBBS, MPH, Chandana A Reddy, MS, Nathan A Pennell, MD PhD, Vamsidhar Velcheti, MD, Keith R McCrae, MD, Alok A Khorana, MD

Blood (2019) 134 (Supplement_1): 3651.

https://doi.org/10.1182/blood-2019-128189

Published: 2019

Journal Articles

Carcinocythemia with Microfilaria: Two Diverse Pathologies in One Case

Swagatika Samal, MBBS MD, Shruti Mishra, MBBS, MD PDF Hematology, Rasheeda Mohamedali, MBBS, Kishore Kumar, MBBS, MD DM

Blood (2019) 134 (Supplement_1): 4867.

https://doi.org/10.1182/blood-2019-131393

Published: 2019

Journal Articles

Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of Stroke

Dipty Jain, MD, Kavitha Ganesan, MBBS, Sati Sahota, Deepika S. Darbari, MD, Lakshmanan Krishnamurti, MD, Fenella Jane Kirkham, MD

Blood (2019) 134 (Supplement_1): 2279.

https://doi.org/10.1182/blood-2019-131416

Published: 2019

Journal Articles

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Shady Adnan Awad, MD, Helena Hohtari, MD, Komal Kumar Javarappa, PhD, Tania Brandstoetter, Daehong Kim, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Soili Kytölä, PhD, Kimmo Porkka, Eszter Doma, PhD, Veronika Sexl, MD PhD, Matti Kankainen, PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 190.

https://doi.org/10.1182/blood-2019-126584

Published: 2019

Journal Articles

Immune Sculpting of Clonal Hematopoiesis in Advanced and Metastatic Solid Tumors

Eti Sinha, Bhavneet Binder, Olivier Elemento, PhD, Duane C. Hassane, PhD

Blood (2019) 134 (Supplement_1): 3721.

https://doi.org/10.1182/blood-2019-132222

Published: 2019

Journal Articles

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Donna E Reece, MD, Giovanni Piza Rodriguez, MD, Mariela A Pantoja, PhD MSc, Darrell J White, MD, Christopher P Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Martha L Louzada, MDMSc, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger E Tiedemann, MBChB, PhD, Harminder K Paul, MSc, Christine I Chen, MD

Blood (2019) 134 (Supplement_1): 4570.

https://doi.org/10.1182/blood-2019-129357

Published: 2019

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

Chiaki Naito, MD, Hiroaki Shimizu, MD PhD, Yuri Miyazawa, MD PhD, Takuma Ishizaki, MD PhD, Akihiko Yokohama, MD PhD, Takayuki Saito, MD PhDProf, Norifumi Tsukamoto, MD PhD, Hiroshi Handa, MD PhD

Blood (2019) 134 (Supplement_1): 5434.

https://doi.org/10.1182/blood-2019-127956

Published: 2019

Journal Articles

Stenosis Outcome at 1 and 3 Years after Transplantation Vs Standard-Care in Children with Sickle-Cell Anemia and Abnormal Transcranial Doppler with Stroke or No-Stroke History

Blood (2019) 134 (Supplement_1): 2271.

https://doi.org/10.1182/blood-2019-122699

Published: 2019

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group

Blood (2018) 132 (Supplement 1): 45.

https://doi.org/10.1182/blood-2018-99-116648

Published: 2018

Journal Articles

A Small Nucleolar RNA Linked to Diamond-Blackfan Anemia

Adeline Mayeux, Nathalie Montel-Lehry, Manon Saby, Aurore Anton, Narjesse Karboul, Julie Galimand, Helene Bourdeau, Jonathan Levy, Anne-claude Tabet, Mohandas Narla, DSc, Alyson W. MacInnes, Pascale Dufourcq, Patrick Blader, Thierry Leblanc, Marie-francoise O' Donohue, Pierre-Emmanuel Gleizes, Lydie Da Costa

Blood (2018) 132 (Supplement 1): 1299.

https://doi.org/10.1182/blood-2018-99-110663

Published: 2018

Journal Articles

Hypercalcemia- Leukocytosis Syndrome: A Rare Ominous Indicator in Lung Cancer

Taylor Hanson, Ravi Patel, DO, Nitasa Sahu, MD, Zain Ayaz, MD, Julie Caler, Pharm.D, Kirk Jones, Pharm.D, Rohit Jain, MBBS

Blood (2018) 132 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2018-99-112705

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)

Sheeba K. Thomas, MD, Jatin J. Shah, MD, Ashley N. Morphey, RN, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Krina K. Patel, MDMSc, Carla P Miller, RN, Suzanne Phillips, RN, Brandon N. Crumpton, Ralph J. Johnson, PhD, Lei Feng, MS, Swaminathan P Iyer, MD, Behrang Amini, MD PhD, Donna M. Weber, MD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2018-99-116464

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Blood (2018) 132 (Supplement 1): 298.

https://doi.org/10.1182/blood-2018-99-115418

Published: 2018

Journal Articles

Kinetic Catalytic Inhibition and Cell-Based Analysis, Not Just Target Binding, Are Required to Assess Kinase Selectivity of Covalent Inhibitors: Comparable BTK vs TEC Selectivity Profile for Ibrutinib and Acalabrutinib

Melissa Hopper, MS, Tarikere Gururaja, PhD, Taisei Kinoshita, PhD, James P. Dean, Ronald Hill, PhD, Ann Mongan, PhD

Blood (2018) 132 (Supplement 1): 3498.

https://doi.org/10.1182/blood-2018-99-110849

Published: 2018

Journal Articles

Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments

Blood (2018) 131 (17): 1931–1941.

https://doi.org/10.1182/blood-2017-07-797209

Published: 2018

Includes: Supplemental data

NARROW

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database

Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study

Carcinocythemia with Microfilaria: Two Diverse Pathologies in One Case

Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of Stroke

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Immune Sculpting of Clonal Hematopoiesis in Advanced and Metastatic Solid Tumors

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

Stenosis Outcome at 1 and 3 Years after Transplantation Vs Standard-Care in Children with Sickle-Cell Anemia and Abnormal Transcranial Doppler with Stroke or No-Stroke History

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group

A Small Nucleolar RNA Linked to Diamond-Blackfan Anemia

Hypercalcemia- Leukocytosis Syndrome: A Rare Ominous Indicator in Lung Cancer

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Kinetic Catalytic Inhibition and Cell-Based Analysis, Not Just Target Binding, Are Required to Assess Kinase Selectivity of Covalent Inhibitors: Comparable BTK vs TEC Selectivity Profile for Ibrutinib and Acalabrutinib

Alterations in the Rho pathway contribute to Epstein-Barr virus–induced lymphomagenesis in immunosuppressed environments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only